A phase 3 study for chikungunya vaccine after passing midstage test

The chikungunya vaccine, known as MV-CHIK, hit its primary goal in the phase 2 trial, and Themis is now eyeing a move into phase 3. The company based its chikungunya shot on its measles vector platform, licensed from Institut Pasteur.

Contact Us

    Add a Comment

    Your email address will not be published. Required fields are marked *